Jan. 12 at 12:28 PM
$AXSM Finally puts to rest any doubts about whether this is a legitimate commercial stage biotech. Prelim 2025 net revenue is
$638.5 million, up 66% YOY and above their own
$500–
$600 million guidance, driven by AUVELITY surpassing
$500 million in annual sales with a
$155 million fourth quarter alone. SUNOSI continues to throw off a steady
$125 million revenue base, while recently launched SYMBRAVO, is already showing a meaningful Q4 run-rate. With Q4 revenue of
$196 million implying an annualized run rate approaching
$800 million before any new approvals or indications, this update makes it clear that Axsome has crossed into a new level that the market is STILL underestimating.
